Menggunakan pengobatan berbantuan medikasi (buprenorfin/metadon) untuk kecanduan opioid vs. pemulihan berbasis pantangan saja
Jika Anda bertindak
Pengobatan berbantuan medikasi (MAT)
18%
Jika Anda tidak bertindak
Pemulihan berbasis pantangan saja (tanpa obat)
70%
Persentase orang yang kemudian menyesali setiap pilihan. Diagram batang dan catatan lengkap ditampilkan di bawah.
Kesehatan
Terakhir ditinjau 2026-05-22
Kualitas bukti 4.25/5
Skor tinjauan delapan dimensi terhadap
rubrik kualitas
. Setiap dimensi dinilai 1–5.
D1 Verifikasi sumber
4/5
D2 Otoritas & independensi sumber
5/5
D3 Akurasi tingkat penyesalan
5/5
D4 Keterbandingan sumber
4/5
D5 Pola Gilovich
5/5
D6 Kualitas prosa
4/5
D7 Kelengkapan peringatan
3/5
D8 Kualitas sampel
4/5
Rata-rata4.25/5
Data proksi — tidak ada survei penyesalan langsung untuk keputusan ini. Tingkat diturunkan dari skor kepuasan dan data hambatan akses daripada pertanyaan yang langsung menanyakan tentang penyesalan. Lihat peringatan di bawah.
Penyesalan atas tindakan
Pengobatan berbantuan medikasi (MAT)
18%
18% pasien MAT tidak puas dengan obatnya sendiri (proksi ketidakpuasan-obat, bukan ukuran penyesalan atas pilihan MAT-vs-abstinensi)
Orang dewasa dengan gangguan penggunaan opioid menggunakan buprenorfin/nalokson atau metadon
data ulasan media sosial lintas-bagian; tidak ada cakrawala retrospektif tetap
Penyesalan atas kelambanan
Pemulihan berbasis pantangan saja (tanpa obat)
70%
~70% orang yang menyelesaikan detoksifikasi opioid tanpa obat berkelanjutan mengalami kambuh dalam 12–36 bulan (tingkat kekambuhan klinis, bukan ukuran penyesalan atas pilihan hanya-abstinensi)
Orang dewasa dengan gangguan penggunaan opioid yang menyelesaikan detoksifikasi rawat inap atau perumahan tanpa farmakoterapi berkelanjutan
12-36 bulan pasca-detoksifikasi
% menyesal dengan pilihan ini
Pengobatan berbantuan medikasi (MAT)Pemulihan berbasis pantangan saja (tanpa obat)
18%70%
inaction dominates — Tidak bertindak mendominasi — sebagian besar menyesali karena tidak bertindak.
Keputusan terkait
Keputusan yang serupa secara semantik — area yang sama, kompromi yang berbeda.
Medication-assisted treatment (MAT) with buprenorphine, methadone, or naltrexone is now
the evidence consensus for opioid use disorder, yet a substantial fraction of people with
OUD still pursue abstinence-only recovery — through 12-step programs, residential detox, or
counselling without pharmacotherapy — out of preference, stigma, or limited access. A 2023
NLP analysis of 4,048 patient reviews of buprenorphine/naloxone and methadone found that 82%
of reviewers reported satisfaction with their medications and only 18% were dissatisfied.
That 18% dissatisfaction figure is the closest available proxy for action-side regret, though
it is a ceiling estimate: a dissatisfied patient may still, in retrospect, endorse the choice
of medication over abstinence given the alternative outcomes.
The inaction side carries a harder clinical penalty. Post-detoxification literature
consistently reports relapse rates of 72–88% within 12–36 months among patients who
complete opioid detoxification without ongoing pharmacotherapy (PMC5046044). Dunn, Sigmon
et al.’s 2011 systematic review found that only 20% of patients leaving residential
detoxification remained abstinent from illicit opioid use at 30 days; the median opioid-
negative rate at first post-taper follow-up across studies was 23%. A 70% midpoint of the
12–36 month relapse range is used as the inaction-side proxy, on the reasoning that patients
who relapse after abstinence-only treatment — particularly those who subsequently accept
MAT — frequently report wishing they had started medication earlier. No large-scale
retrospective survey directly asks abstinence-only patients whether they regret not using
medication, so this remains a proxy framing.
Barriers to starting MAT are well-documented and culturally entrenched. Bremer et al. (2023),
comparing OUD-treatment barriers self-reported on social media against those found in published
literature, found that stigma — including viewing buprenorphine as “a crutch” or “trading one
addiction for another” — was the single most prominently reported barrier, appearing in 78.9%
of reviewed publications and 47.6% of social-media barrier mentions. This stigma layer is what
makes the temporal dynamics relevant: patients who initially resist MAT due to self-stigma
and later relapse into active use are precisely the group expected, under Gilovich and
Medvec’s framework, to experience inaction regret once the counterfactual (medication-
supported stability) becomes visible. The 52-point gap between proxy rates should be read
cautiously — it compares dissatisfaction with clinical failure, not two symmetrical
retrospective measures — but the directional signal is clear: relapse after abstinence-only
treatment is a categorically harder clinical outcome than dissatisfaction with a medication,
which is why the inaction side of this comparison carries the heavier long-term cost.
Sumber: tindakan
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
1/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]JMIR Infodemiology — Predicting Patient Satisfaction With Medications for Treating Opioid Use Disorder: Case Study Applying Natural Language Processing to Reviews of Methadone and Buprenorphine/Naloxone on Health-Related Social Media
Terverifikasi
Telaah sejawat
82% of patients reported satisfaction with their OUD medication; 18% were unsatisfied
Kutipan
“"Our statistical analysis revealed that 18% of the patients were unsatisfied with the treatment medication and 82% reported satisfaction with targeted medications."
”
Data sumber dari
2023-01-23
Diakses
2026-05-22
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Omranian et al. 2023, JMIR Infodemiology, DOI 10.2196/37207. NLP analysis of 4,048 patient reviews of buprenorphine/naloxone and methadone from health-related social media. Three-quarters of reviewers used buprenorphine/naloxone, one-quarter methadone. Regret proxy: 18% dissatisfaction rate used as upper-bound estimate of action-side regret because no large-scale retrospective survey asks MAT patients whether they regret choosing medication over abstinence. Dissatisfaction is a weaker proxy than retrospective regret — it likely overstates regret, since a dissatisfied patient may still endorse the decision as correct in hindsight. This is a ceiling proxy, not a floor.
[2]Frontiers in Public Health (PMC) — Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature
Telaah sejawat
Stigma was the most prominently reported barrier to OUD treatment in published literature, occurring in 78.9% of the publications reviewed; in social-media data, 47.6% of barrier mentions were stigma-related
Kutipan
“"For published literature, stigma was the most prominently reported barrier, occurring in 78.9% of the publications reviewed, followed by financial and/or logistical issues to receiving medication treatment (73.7%), gender-specific barriers (36.8%), and fear (31.5%)."
”
Data sumber dari
2023-04-19
Diakses
2026-05-22
Perhitungan
Bremer et al. 2023, Frontiers in Public Health 11:1141093, DOI 10.3389/fpubh.2023.1141093, PMID 37151596. Compares OUD-treatment barriers self-reported on social media against barriers found in published literature. Corroborates that stigma is the single most common barrier to MOUD uptake — the most prominently reported barrier in 78.9% of reviewed publications and 47.6% of social-media barrier mentions — supporting the action-side regret-proxy framing: some patients who later accept MAT report wishing they had started sooner after years of stigma-driven reluctance. This source is directional evidence for the proxy, not a quantified regret rate.
Sumber: tidak bertindak
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]Journal of Substance Abuse Treatment (PMC) — Predictors of Relapse after Inpatient Opioid Detoxification during 1-Year Follow-Up
Terverifikasi
Telaah sejawat
Relapse rate after opioid detoxification ranges from 72 to 88% after 12–36 months; 1-year relapse rate in this study was 31.5% due to adjunctive naltrexone maintenance
Kutipan
“"Relapse rate after opioid detoxification ranges from 72 to 88% after 12–36 months, despite multidisciplinary endeavors, though a six-month controlled study has shown lower relapse rate (32–70%)."
”
Data sumber dari
2016-09-28
Diakses
2026-05-22
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
PMC5046044, published in Journal of Substance Abuse Treatment 2016. Regret proxy: a relapse within 12–36 months after choosing abstinence-only treatment is used as a proxy for inaction-side regret, on the reasoning that patients who relapse after abstinence-only treatment — especially those who later accept MAT — frequently report regret at not having used medication earlier. No large-scale retrospective survey directly asks abstinence-only patients whether they regret declining medication. The 70% point estimate is the midpoint of the 72–88% literature range reported in this article; it likely underestimates long-term regret since short-term relapse is a proxy and not all relapsers would endorse regret about the original abstinence choice. The study's own 1-year figure (31.5% relapse) is NOT used here because those patients received naltrexone maintenance, which makes it a MAT cohort, not abstinence-only.
[2]Drug and Alcohol Dependence (PMC) — The Association between Outpatient Buprenorphine Detoxification Duration and Clinical Treatment Outcomes: A Review
Terverifikasi
Telaah sejawat
Only 20% of patients leaving residential detoxification remain abstinent at 30 days post-detoxification; median opioid-negative rate at first post-taper follow-up was 23% (range 8.4–52%)
Kutipan
“"only a minority (41% and 20%) of patients leaving a residential detoxification remain abstinent from illicit opioid use at 7 and 30 days post-detoxification, respectively."
”
Data sumber dari
2011-07-08
Diakses
2026-05-22
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Dunn, Sigmon et al. 2011, Drug Alcohol Depend 119(1-2):1–9, PMID 21741781. Systematic review of outpatient buprenorphine detoxification outcomes. The statistic (20% abstinent at 30 days) comes from the cited residential-detox literature base, not from the buprenorphine-detox studies themselves. This is corroborating evidence that detoxification-only treatment produces high early relapse rates, supporting the 70% proxy figure derived from the 72–88% 12-36 month range. Used here to establish the short-term relapse floor (80% already relapsed within 30 days), consistent with the longer-term range.
Catatan
Kedua sisi hanya-proksi — tidak ada survei skala besar yang secara langsung menanyakan baik pasien MAT apakah mereka menyesal memilih obat ketimbang abstinensi, maupun pasien hanya-abstinensi apakah mereka menyesal tidak minum obat. Tingkat sisi-tindakan (18%) adalah proksi ketidakpuasan dari ulasan media sosial atas obat OUD; pasien yang puas lebih mungkin memposting ulasan, menciptakan bias seleksi yang mungkin meremehkan ketidakpuasan dalam populasi nyata. Tingkat sisi-diam (70%) adalah proksi kekambuhan dari literatur tindak lanjut pasca-detoksifikasi; kambuh tidak setara dengan penyesalan retrospektif — sebagian pasien yang kambuh tidak mendukung penyesalan atas pilihan abstinensi awal, sementara yang lain yang tetap abstinen mungkin tetap menyesal tidak menggunakan obat lebih awal. Perbandingan karenanya adalah antara ketidakpuasan atas pengobatan yang dipilih dan kegagalan klinis dari jalur pengobatan, bukan antara dua ukuran penyesalan yang simetris. Selain itu, "hanya-abstinensi" mencakup program yang heterogen (12 langkah, SMART Recovery, residensial, rawat jalan), dan MAT mencakup buprenorfin, metadon, dan naltrekson lepas-lambat — profil penyesalan di antara sub-tipe ini kemungkinan berbeda secara bermakna. Pasien yang menolak MAT sering menyebut stigma khusus-obat (memandangnya sebagai "menukar satu kecanduan dengan yang lain"), yang merupakan keyakinan yang dapat menghasilkan penyesalan pasca-kambuh ketimbang penyesalan pasca-MAT. Di bawah kerangka temporal Gilovich dan Medvec, penyesalan atas tidak bertindak (tidak minum obat meski ada bukti yang tersedia) diperkirakan mendominasi dalam jangka panjang untuk keputusan ini karena perbedaan hasilnya — penggunaan zat yang berlanjut dan risiko overdosis vs. dorongan yang tertekan — bersifat konkret dan terlihat secara retrospektif.
